SEC Form 4 · accession 0001615774-18-013954
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald Eric D'Ambrosio
Officer — Chief Financial Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 5:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EMPLOYEE STOCK OPTION (right to purchase)F1 | $1.46 | Dec 3, 2018 | A | 26,500 | A | Dec 3, 2018 | Dec 3, 2028 | Common Stock | 26,500 | 26,500 | D |
Explanation of responses
- F1On December 03, 2018, the Reporting Person was granted an option to purchase 26,500 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. 8,834 of the options vested on the grant date (December 3, 2018), with 8,833 vesting on the first anniversary of the grant date and 8,833 vesting on the second anniversary of the grant date.